Journal
BIOTECHNOLOGY LETTERS
Volume 30, Issue 8, Pages 1323-1330Publisher
SPRINGER
DOI: 10.1007/s10529-008-9689-2
Keywords
E. coli; heterologous host; natural products; polyketides
Categories
Funding
- NIGMS NIH HHS [R25 GM073177-01] Funding Source: Medline
Ask authors/readers for more resources
Heterologous natural product biosynthesis has emerged as a strategy to produce medicinal compounds that pose challenges to conventional production routes. Polyketide compounds, an important class of natural products with wide-ranging therapeutic value, have been heterologously produced through Escherichia coli, presenting new opportunities to realize the medicinal potential of polyketide natural products. However, current production levels are often suboptimal when compared to native strain producers or heterologous theoretical yields. This problem provides an excellent opportunity to apply and further develop current metabolic engineering tools.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available